A study to assess efficacy and safety of salvage Ruxolitinib treatment for multidrug-resistant GVHD in haplo-HSCT recipients
Latest Information Update: 29 Jan 2021
At a glance
- Drugs Ruxolitinib (Primary) ; Antithymocyte globulin; Busulfan; Ciclosporin; Cyclophosphamide; Cytarabine; Methotrexate; Mycophenolate mofetil; Semustine
- Indications Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 29 Jan 2021 New trial record
- 01 Jan 2021 Results published in the Annals of Hematology